Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Azacitidin Zentiva 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Azacitidine 25 mg/mL powder for suspension for injection, SY-1425, Placebo for Tamibarotene (SY-1425), AZACITIDINE
Lacuna Pharma Pty Ltd
Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome
1 trial -
Azacitidine Combined With Venetoclax and ATRA group
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Azacitidine, Cedazuridine, Azacitidine, Vidaza 25 mg/ml powder for suspension for injection, Azacitidine, Cedazuridine
Taiho Pharma Netherlands B.V.
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
1 trial -
Azelastine hydrochloride and Fluticasone propionate
Teva Pharma GmbH
Seasonal Allergic Rhinitis
1 trial -
Azetukalner
Xenon Pharmaceuticals
Bipolar Depression
1 trial -
Azetukalner
Xenon Pharmaceuticals
Bipolar Disorder
1 trial -
Azilsartan medoxomil/placebo
Takeda
Essential Hypertension
1 trial -
Azithromycin
Cardiff Oncology
Bronchopulmonary Dysplasia
1 trial -
Azvudine
Shanghai Henlius Biotech
SARS-CoV-2 Infection
1 trial -
B/F/TAF
Gilead Sciences Ireland UC
HIV-1/HBV Co-Infection
1 trial -
B/F/TAF (Adult Strength)
Gilead Sciences Ireland UC
HIV-1 Infection
1 trial -
B007
BRIGHT MINDS BIOSCIENCES INC.
Generalized Myasthenia Gravis
1 trial -
B007
BRIGHT MINDS BIOSCIENCES INC.
Primary Membranous Nephropathy
2 trials -
B013+Nab-Paclitaxel
BRIGHT MINDS BIOSCIENCES INC.
Triple Negative Breast Cancer (TNBC)
1 trial -
BAF312, FINGOLIMOD HYDROCHLORIDE, BAF312, BAF312, Placebo to Ofatumumab (OMB157) [Kesimpta], BAF312, OFATUMUMAB, BAF312, Placebo to Siponimod (BAF312) [Mayzent] film-coated tablets, Placebo to Fingolimod (FTY720) [Gilenya] 0.25mg & 0.5mg, FINGOLIMOD HYDROCHLORIDE
Novartis Pharmaceuticals
Multiple Sclerosis in pediatric patients
1 trial -
BARICITINIB, ADALIMUMAB, ADALIMUMAB, Baricitinib, BARICITINIB, BARICITINIB
Eli Lilly Co.
Uveitis
1 trial -
BARICITINIB, BARICITINIB, Placebo to match LY, Baricitinib
Eli Lilly Co.
Diabetes Mellitus, Type 1
1 trial -
BARICITINIB, Baricitinib, BARICITINIB, BARICITINIB
Eli Lilly Co.
Juvenile Idiopathic Arthritis
1 trial -
BARICITINIB, Baricitinib, Placebo to match LY, BARICITINIB
Eli Lilly Co.
Diabetes Mellitus, Type 1
1 trial -
BARICITINIB, TRIAMCINOLONE ACETONIDE, BARICITINIB, HYDROCORTISONE, Baricitinib, Placebo to match 4 mg tablet, BARICITINIB, HYDROCORTISONE, Hydrocutan Creme 1 %, Placebo to match 2mg tablet, Placebo to match 1mg tablet, Placebo to match 2mg/ml oral suspension
Eli Lilly Co.
Atopic Dermatitis
1 trial -
BAT5906 injection
Bio-Thera Solutions
Diabetic Macular Edema (DME)
1 trial -
BAX 326
Takeda
Hemophilia B
1 trial -
BAX 326 (Recombinant factor IX)
Takeda
Hemophilia B
1 trial -
BAX326
Takeda
Hemophilia B
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources